http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/list Mynewsdesk nyhetsstrøm direkte fra kilden http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 sv 15 Wed, 20 Mar 2013 10:05:23 +0100 Beslutningstakere i helsesektoren bruker i større utstrekning enn tidligere data fra registerbaserte studier når de tar beslutninger om kliniske prioriteringer og refusjon av legemidler. http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/kort-om-real-world-evidence-rwe-25724?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/kort-om-real-world-evidence-rwe-25724?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 04 Nov 2011 13:49:33 +0100 http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/bakgrunnsstoff-om-lungekreft-og-iressa-16500?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/bakgrunnsstoff-om-lungekreft-og-iressa-16500?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 04 Nov 2011 13:48:41 +0100 http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/bakgrunnsstoff-om-egfr-mutasjoner-og-testing-16499?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/bakgrunnsstoff-om-egfr-mutasjoner-og-testing-16499?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Fri, 04 Nov 2011 13:45:05 +0100 I løpet av 2011 vil over to tusen mennesker få diagnosen lungekreft i Norge, og stadig flere av disse vil være kvinner. Mange kunne vært reddet hvis de hadde forstått symptomene og kommet raskere til legen. http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/myter-og-fakta-om-lungekreft-16498?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/myter-og-fakta-om-lungekreft-16498?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Tue, 01 Nov 2011 12:07:29 +0100 http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/om-vimovo-faktamateriale-for-journalister-nsaid-16398?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/om-vimovo-faktamateriale-for-journalister-nsaid-16398?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Tue, 01 Nov 2011 12:06:53 +0100 http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/om-vimovo-faktamateriale-for-journalister-16397?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/om-vimovo-faktamateriale-for-journalister-16397?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB Tue, 01 Nov 2011 12:06:14 +0100 http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/faktamateriale-for-journalister-om-artrose-16395?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document http://www.mynewsdesk.com/no/pressroom/astrazeneca/document/view/faktamateriale-for-journalister-om-artrose-16395?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document AstraZeneca AB